Q-omics provides the consensus-scored ZFP91 profile across patient tissues and cancer cell-line models. ZFP91 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFP91 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZFP91 RNA expression shows 20,225 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ZFP91 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP91 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP91 survival associations across molecular data types. ZFP91 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP91 RNA expression–survival associations across cancer types. High ZFP91 expression shows unfavorable associations in ACC, PAAD, BLCA and KICH, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFP91 RNA expression.
This table summarizes ZFP91 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZFP91. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP91 shows lower tumor expression in COAD and higher tumor expression in HNSC, LIHC, BRCA, LUSC and STAD. The HNSC box plot shows higher ZFP91 RNA expression in tumor versus normal tissue (log2 FC = +0.876, t-test p < 0.001).
This table shows molecular features associated with ZFP91 in patient tissues and cancer cell lines. In patient samples, ZFP91 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP91 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
